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Abstract
Recent efforts to improve survival in patients with locally advanced esophageal carcinoma have combined both
systemic and local therapy. However, the role of neoadjuvant chemoradiotherapy in technically operable IIa-III
esophageal carcinoma is still unresolved.
Findings
We have read with interest the report from Hurmuzlu
and coll [1] on the outcome of induction therapy (IT)
plus surgery versus surgery alone in locally advanced
operable esophageal cancer (OC).
The report is of great speculative interest given the
consistently poor prognosis of OC whatever the thera-
peutic strategy adopted: so far, in fact, there is no gen-
eral consensus on the appropriate treatment for such a
dreadful condition. Specifically, the role of chemo-radio-
therapy administered pre-operatively in resectable cstage
IIa-III OC is still discussed.
Scarce data are available from the literature and these
are not consistent. In fact some experiences [2,3] con-
clude with positive recommendations to adopt the tri-
modality approach and others [4] conclude with oppo-
site position: that IT should not be adopted in OC that
a r er e s e c t a b l ef o l l o w i n gt h ec linical staging assessment.
As already advocated by Pereira [5], the indication for
IT for resectable OC remains largely not evidence-based
substantially due to methodological biases in the trials
that can be summarised as follows: different tumour
stages included, no standardized preoperative diagnostic
procedure and, last but not least, the great heterogenity
of surgical treatment.
In this scenario of substantial absence of a large base of
methodologically correct evidence and agreed guidelines
we consider the results from [1] of significant clinical
value and concur in advocating for further evidence
stemming from large scale prospective randomised trials.
Ideally, these should be designed valuing the past experi-
ences to address the methodological biases with the pre-
cise task to assess whether IT should be administered
before surgery in resectable OC. These trials should: a)
distinguish between hystologies (squamous cell vs adeno-
carcinoma); b) include an optimal pre-operative staging
with EUS, high quality CT and PET scan to assess the
extent of the loco-regional disease and exclude distant
metastases and c) include a standardized surgical treat-
ment with extended lymph node dissection. Only by such
trials the role of IT in the treatment of OC can be
cleared. More convincing arguments, in fact, need to sup-
port any proposed change in clinical behaviour.
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